Promises of specific shade changes (three tones fairer guaranteed)
[13] [14] Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should not receive GLP-1 medications due to the theoretical risk of thyroid C-cell tumors
Substance use and psychotic disorders, seizures, neurocognitive disorders (including Alzheimers disease and dementia), coagulation disorders, cardiometabolic disorders (heart attack, heart failure, ischemic stroke, and hemorrhagic stroke, pulmonary embolism, pulmonary hypertension, coagulopathy and clotting disorders) chronic kidney disease, COPD, pneumonia, liver failure, inflammatory bowel disease, liver cancer) all significantly declined
(PubMed) van Dam DG, Beijers AJ, Vreugdenhil G